Oculis Pivots to Neuro-Ophthalmology with Privosegtor Lead Asset
Event summary
- Oculis reports $282.3 million in cash reserves as of June 30, 2026, providing runway into 2H 2029.
- Privosegtor's PIONEER-1 trial for optic neuritis is progressing with global site activations and positive FDA pre-IND feedback for acute MS relapses.
- Licaminlimab's PREDICT-1 genotype-based trial in dry eye disease has >45% of patients randomized.
- Oculis will host an R&D Day in Q4 2026 to update on Privosegtor’s clinical development.
The big picture
Oculis is doubling down on neuro-ophthalmology with Privosegtor as its lead asset, leveraging positive regulatory feedback from the FDA. The company's strong cash position provides a buffer for its strategic shift, but execution risks remain in clinical trials and market positioning against existing therapies.
What we're watching
- Regulatory Momentum
- Whether the FDA’s positive feedback on Privosegtor will accelerate its development timeline for acute MS relapses.
- Trial Execution
- The pace at which Licaminlimab's PREDICT-1 trial completes enrollment and reports topline results by year-end.
- Cash Utilization
- How Oculis manages its $282.3 million cash reserves to support its strategic pivot and upcoming milestones.